Up next

CEOs, Senior Executives Highlight Mfg Expansions at the DCAT Member Company Announcement Forum

CEOs and senior executives from DCAT Member Companies highlighted their companies’ major news at the DCAT Member Company Announcement Forum at DCAT Week. Manufacturing expansions for peptides, biomanufacturing, and sterile manufacturing led the news. 

CEOs and senior executives from DCAT Member Companies highlighted their companies’ major news at the DCAT Member Company Announcement Forum at DCAT Week. Manufacturing expansions for peptides, biomanufacturing, and sterile manufacturing led the news. 

By Patricia Van Arnum, Editorial Director, DCAT, pvanarnum@dcat.org

CEO and senior executives from DCAT Member Companies highlighted their companies major news at the DCAT Member Company Announcement Forum at DCAT Week, the flagship event of the Drug, Chemical & Associated Technologies Association (DCAT). Companies reported the latest in expansion plans across the bio/pharmaceutical manufacturing value chain: from drug substances (small-molecules and biologics) to drug products (solid dosage and injectable product forms). In all, 20 companies took to the podium to make their announcements. The program kicked off DCAT Week on Monday March 17th, 2025.

Led by the success of glucagon-like peptide-1 (GLP-1) agonists, a number of companies reported expansions in peptide development and manufacturing, punctuated by CordenPharma’s more than $1-billion expansion plan. Other companies proceeding with peptide expansions, at various scales, included BioDuro, Neuland Laboratories, SK pharmteco, and Axplora (through an expansion on large-scale high-performance liquid chromatography (HPLC) and continuous chromatography for API purification, including peptides).

Other companies are proceeding with expansions in fine-chemicals, small-molecule active pharmaceutical ingredients (APIs), either general expansions or capabilities for specialized products, such as antibody drug conjugates or other conjugated products. These companies included SK pharmteco, BioDuro, Procos, Esteve, Lonza, and Lacamas Laboratories.

Multi-billion dollar expansions in biologics (drug substance) were also a highlight of the Member Company Announcement Forum with FUJIFILM Diosynth Biotechnologies and Lonza providing updates of their large-scale projects. Although not at the same scale, Thermo Fisher Scientific provided an update of its biomanufacturing expansions. For early-stage research, Bio X Cell, a producer of functional in vivo antibodies for translational research, highlighted its new distribution center in China. Also, Avantor outlined a large expansion in its hydration capabilities to support bioprocessing and other processes.   

On the drug-product side, Thermo Fisher Scientific provided details of its expansions in fill-finish and sterile manufacturing as did other companies, which reflected a truly global reach: Symbiotec Pharmalab (India), Boston Oncology (Saudi Arabia), RV Group (Vietnam), JGL (Croatia), and Upperton Pharma Solutions (UK). Also, Ursatec provided an update on its expansion strategy for the US market for its preservative-free drug-delivery systems.

One announcement that stood out for its uniqueness from a technology view was from the CMDO Bora Pharmaceuticals, which outlined how the company was using and plans to use artificial intelligence in its operations.

Details of each company’s announcement can be found below. 

Recent Feature Articles

Pharma & Tariffs: US Supreme Court Weighs In

By
The US Supreme Court heard oral arguments in cases involving the legality of reciprocal tariffs, country-by-country tariffs imposed through a series of trade deals and executive actions. Is tariff relief a possibility or not?
Wave

The Next Wave of Biologics: What’s Trending

By
Which biologics have received approval by FDA’s Center for Drug Evaluation and Research thus far in 2025, and how are they positioned in the market? What other market contenders loom in the industry’s pipeline?

The Battle in the Obesity Drug Market Heats Up

By
Novo Nordisk’s bid to best a previous offer from Pfizer to acquire the bio/pharma company, Metsera, is the latest in the competitive obesity drug market. What are the assets the companies are vying for, and how do they stack up against other contenders in the obesity drug market?

Emerging Pharma: On the Industry’s Radar

By
Partnering deals and MA& among the large bio/pharma companies and smaller companies not only reflect strategic decisions by the bio/pharma majors to build their product portfolios, but also put these smaller companies on the industry map. Which companies are making the mark in 2025?